What did @courtneyhuntmd actually say?
The claim is specific and provocative: testosterone is "made" in the mitochondria, low testosterone signals mitochondrial dysfunction, and that dysfunction is a precursor to Alzheimer's, Parkinson's, and heart disease. She also argues that testosterone replacement therapy, whether injections, pellets, or creams, is a "band-aid" that doesn't fix the underlying problem. She says one patient raised his testosterone to over 700 in a month through her group program.
This is not standard endocrinology. It mixes real science (mitochondria do play a role in steroidogenesis) with significant overreach (low T predicts dementia). The framing is designed to position TRT as inadequate and her approach as superior. That's a commercial argument dressed as a clinical one, and it deserves scrutiny.
Does the science back this up?
Partially, but not in the way she presents it. Mitochondria are genuinely involved in testosterone synthesis, but the leap from "mitochondrial involvement" to "low T means your mitochondria are failing and dementia is coming" is not supported by current evidence.
The steroidogenesis pathway does begin in the mitochondria. The enzyme CYP11A1, located on the inner mitochondrial membrane, converts cholesterol to pregnenolone, the precursor to testosterone. This is real biochemistry (Miller, 2013, Endocrine Reviews). So the mitochondria-testosterone connection is not invented.
However, low testosterone has multiple causes: aging, obesity, sleep apnea, chronic stress, medication side effects, and primary hypogonadism. Attributing it predominantly to mitochondrial dysfunction is a reductive framing that ignores most of the clinical picture. The evidence linking low testosterone specifically to dementia risk is associative, not causal. A 2021 meta-analysis (Gillett et al., Journal of Clinical Medicine) found correlations between low T and cognitive decline, but correlation is not a roadmap to causation.
What did they get wrong (or right)?
She got the biochemistry directionally right but extrapolated way too far. Mitochondria are involved in steroid hormone synthesis. That part holds up. The rest does not hold up nearly as well.
Saying low testosterone is "the first sign" of impending neurodegeneration is not a position supported by clinical guidelines from the Endocrine Society or the American Urological Association. Low T is a common, multifactorial condition. Most men with low T do not go on to develop Alzheimer's or Parkinson's. Presenting it that way without qualification is fear-based framing.
The dismissal of TRT as a "band-aid" is also worth challenging. For men with confirmed hypogonadism, testosterone replacement has documented benefits on bone density, mood, libido, and in some populations, cardiovascular markers (Bhasin et al., 2018, New England Journal of Medicine). Calling that a band-aid because it doesn't address mitochondrial health is a false binary. You can treat symptoms and address root causes simultaneously.
The single patient anecdote, one man raising his T to over 700 in a month, is not evidence of anything generalizable. Testosterone levels fluctuate significantly based on time of day, sleep, stress, and lab conditions.
What should you actually know?
If your testosterone is low, get a proper workup before assuming your mitochondria are failing. Clinicians should check for sleep apnea, metabolic syndrome, pituitary function, and medication interactions before landing on a diagnosis of primary hypogonadism or, as this video implies, systemic mitochondrial disease.
Mitochondrial health is a legitimate area of research in aging and metabolism. Lifestyle interventions like resistance training, sleep optimization, and reducing alcohol do support mitochondrial function and have modest documented effects on testosterone levels (Kumagai et al., 2016, European Journal of Applied Physiology). That part of the underlying message is reasonable.
But if you have clinically confirmed hypogonadism with symptoms, TRT is an evidence-based treatment. It is not a failure to address root causes. It is medicine. The framing that any exogenous hormone therapy is inherently inferior to a lifestyle or supplement program is not a clinical position. It is a marketing position. Know the difference before making decisions about your own care.